Japan Tissue Engineering (7774) Fundamentals 2026 — Revenue Analysis | SniperIQ
Japan Tissue Engineering (7774) is a JP-listed Healthcare company in Biotechnology with a market capitalization of ¥25.5B, trading at ¥627.00 on the JPX. This SniperIQ fundamentals page covers Japan Tissue Engineering's valuation, profitability (net margin -33.7%), revenue (¥2.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Japan Tissue Engineering's market cap?
Japan Tissue Engineering (7774) has a market capitalization of approximately ¥25.5B, trading at ¥627.00 on the JPX. Market cap moves with the live share price.
What is Japan Tissue Engineering's P/E ratio?
Japan Tissue Engineering's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Japan Tissue Engineering?
Japan Tissue Engineering runs a net profit margin of -33.7%, a gross margin of 58.1%, and an operating margin of -25.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Japan Tissue Engineering generate?
Japan Tissue Engineering reported revenue of ¥2.2B for fiscal year 2025, with net income of -¥735M and earnings per share (EPS) of -18.09. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Japan Tissue Engineering pay a dividend?
Japan Tissue Engineering does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Japan Tissue Engineering financially healthy?
Japan Tissue Engineering carries a debt-to-equity ratio of 0.00x and a current ratio of 7.46x, with a market beta of 0.62. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Japan Tissue Engineering a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Japan Tissue Engineering (7774) the key facts are: market cap ¥25.5B, revenue ¥2.2B, 52-week range 448-883. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Japan Tissue Engineering's full fundamentals live
Get Japan Tissue Engineering's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.